Business Context and Reporting Period
This Form 8-K, filed on April 3, 2011, by Ducommun Incorporated (Ducommun), announces the entry into a definitive agreement to acquire LaBarge, Inc. (LaBarge). The transaction involves a merger where a Ducommun subsidiary will merge with LaBarge, with LaBarge surviving as a wholly-owned subsidiary. The filing also details concurrent debt financing commitments and a voting agreement with key LaBarge stockholders.
Key Financial Metrics and Transaction Terms
- Acquisition Price: $19.25 per share in cash for outstanding LaBarge common stock.
- Option Treatment: Outstanding options will be cancelled and converted to cash equal to the excess of $19.25 over the exercise price.
- Financing Commitments:
- Senior secured term loan: $190 million.
- Senior secured revolving loan: Up to $40 million.
- Senior unsecured bridge loan: Up to $200 million (expected to be replaced by high-yield senior notes).
- Termination Fee: $12,410,000 payable by LaBarge to Ducommun under specified circumstances.
- Expense Reimbursement: Up to $5,000,000 payable by LaBarge to Ducommun if stockholders do not approve the merger.
- Voting Support: Covered stockholders (executives and directors) holding approximately 19% of LaBarge stock have agreed to vote in favor of the merger.
Material Changes and Transaction Structure
The primary material change is the initiation of the merger process. The transaction is subject to customary closing conditions, including approval by LaBarge stockholders holding two-thirds of outstanding shares and the expiration of the Hart-Scott-Rodino Antitrust waiting period. The "no shop" provision restricts LaBarge from soliciting alternative proposals, subject to a "fiduciary-out" clause allowing the board to consider superior proposals if necessary to fulfill fiduciary duties. The merger agreement terminates if not consummated by September 30, 2011.
Guidance, Outlook, and Risks
Outlook: The parties expect to close the transaction during the summer of 2011. Ducommun held a conference call on April 4, 2011, to discuss the benefits and financing of the merger.
Risks and Contingencies:
- Failure to obtain stockholder approval or satisfy regulatory conditions.
- Inability to secure necessary debt financing.
- Disruption of current operations and employee retention issues.
- Difficulties in integrating LaBarge's business and realizing synergies.
- Impact of increased indebtedness on Ducommun's financial condition.
- Potential legal proceedings following the announcement.
Unusual Items: The filing includes forward-looking statements regarding the benefits of the merger, which are subject to significant risks and uncertainties. The filing explicitly states that representations and warranties in the agreement are for risk allocation between parties and should not be relied upon as factual characterizations of the companies' conditions.
Investor Verification Checklist
- Verify the final terms of the high-yield senior notes offering intended to replace the bridge facility.
- Monitor the LaBarge proxy statement for detailed financial data and the full text of the merger agreement.
- Confirm the status of the Hart-Scott-Rodino Antitrust waiting period.
- Review the specific conditions under which the $12.41 million termination fee and $5 million expense reimbursement are triggered.
- Assess the impact of the $430 million total potential debt commitment on Ducommun's leverage ratios.